Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Pharmaceuticals
|
| gptkbp:clinicalTrials |
often limited
|
| gptkbp:designedFor |
rare diseases
|
| gptkbp:developsStrategiesFor |
grants
tax credits waived fees |
| gptkbp:examples |
gptkb:Yescarta
gptkb:Tisagenlecleucel gptkb:Ilumya gptkb:Tremfya gptkb:Luxturna gptkb:Xyrem gptkb:Onpattro gptkb:Bavencio gptkb:Opdivo gptkb:Brineura gptkb:Voxzogo gptkb:Cerdelga gptkb:Vimizim gptkb:Cayston Breztri Aerosphere Keytruda Dupixent Kalydeco Zolgensma Taltz Zynteglo Siliq Evrysdi Skyrizi Rinvoq Cimzia Epidiolex Imfinzi Xeljanz Cosentyx Kymriah Entyvio Aldurazyme Firdapse Myalept Nexviazyme Qalsody Takhzyro Vyndaqel |
| gptkbp:hasPopulation |
small patient populations
|
| https://www.w3.org/2000/01/rdf-schema#label |
Orphan Drugs
|
| gptkbp:marketSegment |
7 years in the US
|
| gptkbp:offers |
often very high
|
| gptkbp:regulatoryCompliance |
FDA_approved
|